Clinical Trial Update: ARD-101 for Treatment of PWS: The Hunger Elimination or Reduction Objective Trial [Phase 3]

View source ↗

Summary

Phase 3 trial ARD-101 for Prader-Willi syndrome-related hyperphagia has been suspended.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prader-willi Syndrome

Drugs mentioned

• ARD-101

Snippet

Sponsor: Aardvark Therapeutics, Inc. | Conditions: Hyperphagia, Prader-Willi Syndrome | Phase 3 | Status: SUSPENDED